SEARCH

SEARCH BY CITATION

References

  • 1
    Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001; 345: 4152.
  • 2
    Robertson B, Myers G, Howard C, Brettin T, Bukh J, Gaschen B, Gojobori T, et al. Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: proposals for standardization. Arch Virol 1998; 143: 24932503.
  • 3
    Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244: 359362.
  • 4
    Kuo G, Choo GL, Alter HJ, Gitnick GL, Redeker AG, Purcell RH, Miyamura T, et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 1989; 244: 362364.
  • 5
    Major M, Feinstone SM. The molecular biology of hepatitis C. Hepatology 1997; 25: 15271538.
  • 6
    Honda M, Beard MR, Ping LH, Lemon SM. A phylogenetically conserved stem-loop structure at the 5′ border of the internal ribosome entry site of hepatitis C virus is required for cap-independent viral transplantation. J Virol 1999; 73: 11651174.
  • 7
    Kolykhalov AA, Mihalik K, Feinstone SM, Rice CM. Hepatitis C virusencoded enzymatic activities and conserved RNA elements in the 3′ non-translated region are essential for virus replication in vivo. J Virol 2000; 74: 20462051.
  • 8
    Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, Perelson AS. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-α therapy. Science 1998; 282: 103107.
  • 9
    Martell M, Esteban JI, Quer J, Genesca J, Weiner A, Esteban R, Guardia J, et al. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution. J Virol 1992; 66: 32253229.
  • 10
    Bukh J, Miller RH, Purcell RH. Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Semin Liver Dis 1995; 15: 4163.
  • 11
    Alter MJ, Kniszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, Kaslow RA, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341: 556562.
  • 12
    Mahoney K, Tedeschi V, Maertens G, Di Bisceglie AM, Vergalla J, Hoofnagle JH, Sallie R. Genotypic analysis of hepatitis C virus in American patients. Hepatology 1994; 20: 14051411.
  • 13
    Lau JY, Davis GL, Prescott LE, Maertens G, Lindsay KL, Qian K, Mizokami M, et al. Distribution of hepatitis C virus genotypes determined by line probe assay in patients with chronic hepatitis C seen at tertiary referral centers in the United States. Hepatitis Interventional Therapy Group. Ann Intern Med 1996; 124: 868876.
  • 14
    Rubbia-Brandt L, Leandro G, Spahr L, Giostra E, Quadri R, Male PJ, Negro F. Liver steatosis in chronic hepatitis C: a morphological sign suggesting infection with HCV genotype 3. Histopathology 2001; 39: 119124.
  • 15
    Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH. Pathogenesis, natural history, treatment and prevention of hepatitis C. Ann Intern Med 2000; 132: 296305.
  • 16
    Zeuzem S, Lee JH, Franke A, Ruster B, Prummer O, Hermann G, Roth WK. Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alfa. Hepatology 1998; 27: 11491156.
  • 17
    Neumann AU, Lam NP, Dahari H, Davidian M, Wiley TE, Mika BP, Perelson AS, et al. Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. J Infect Dis 2000; 182: 2835.
  • 18
    McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339: 14851492.
  • 19
    Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, et al. Randomised trial of interferon alfa-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alfa-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998; 352: 14261432.
  • 20
    Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358: 958965.
  • 21
    Fried MW, Shiffman ML, Reddy K, Smith C, Marions G, Gonçales FL Jr, Häussinger D, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975982.
  • 22
    Hadziyannis SJ, Cheinquer H, Morgan T, Diago M, Jensen DM, Sette H, Ramadori G, et al. Peginterferon alfa-2a (40kD) (PEGASYS) in combination with ribavirin (RBV): efficacy and safety results from a phase III, randomized, double-blind, multicentre study examining effect of duration of treatment and RBV dose [Abstract]. J Hepatol 2002; 36 (Suppl 1): 3.
  • 23
    Abrignani S, Houghton M, Hsu HH. Perspectives for a vaccine against hepatitis C virus. J Hepatol 1999; 31: 259263.
  • 24
    Forns X, Payette PJ, Ma X, Satterfield W, Eder G, Mushahwar IK, Govindarajan S, et al. Vaccination of chimpanzees with plasmid DNA encoding the hepatitis C virus (HCV) envelope E2 protein modified the infection after challenge with homologous monoclonal HCV. Hepatology 2000; 32: 618625.
  • 25
    Lohmann V, Korner F, Koch J, Herian U, Theilmann L, Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999; 285: 110113.
  • 26
    Blight KJ, Kolykhalov AA, Rice CM. Efficient initiation of HCV RNA replication in cell culture. Science 2000; 290: 19721974.
  • 27
    Ilan E, Arazi J, Nussbaum O, Zauberman A, Eren R, Lubin I, Neville L, et al. The hepatitis C virus (HCV)-trimera mouse: a model for evaluation of agents against HCV. J Infect Dis 2002; 185: 153161.
  • 28
    Mercer DF, Schiller DE, Elliott JF, Douglas DN, Hao C, Rinfret A, Addison WR, et al. Hepatitis C virus replication in mice with chimeric human livers. Nat Med 2001; 7: 927933.
  • 29
    Farci P, Alter HJ, Govindarajan S, Wong DC, Engle R, Lesniewski RR, Mushahwar IK, et al. Lack of protective immunity against reinfection with hepatitis C virus. Science 1992; 258: 135140.
  • 30
    Lai ME, Mazzoleni AP, Argiolu F, De Virgilis S, Balistrieri A, Purcell RH, Cao A, et al. Hepatitis C virus in multiple episodes of acute hepatitis in polytransfused thalassaemic children. Lancet 1994; 343: 388390.
  • 31
    Mehta SH, Cox A, Hoover DR, Wang X-H, Mao Q, Ray S, Strathdee SA, et al. Protection against persistence of hepatitis C. Lancet 2002; 359: 14781483.
  • 32
    Center for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Morb Mortal Wkly Rep 1998; 47 (No. RR-19).
  • 33
    Farci P, Alter HJ, Wong D, Miller RH, Shih JW, Jett B, Purcell RH. A long-term study of hepatitis C virus replication in non-A, non-B hepatitis. N Engl J Med 1991; 325: 98104.
  • 34
    Shimizu YK, Weiner AJ, Rosenblatt J, Wong DC, Shapiro M, Popkin TJ, Houghton M, et al. Early events in hepatitis C virus infection of chimpanzees. Proc Natl Acad Sci USA 1990; 87: 64416444.
  • 35
    Major ME, Mihalik K, Fernandez J, Seidman J, Kleiner D, Kolykhalov AA, Rice CM, et al. Long-term follow-up of chimpanzees inoculated with the first infectious clone for hepatitis C virus. J Virol 1999; 73: 33173325.
  • 36
    Thimme R, Oldach D, Chang K-M, Steiger C, Ray SC, Chisari FV. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 2001; 194: 13951406.
  • 37
    Alter HJ, Seeff LB. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis 2000; 20: 1735.
  • 38
    Alter HJ, Sanchez-Pescador R, Urdea MS, Wilber JC, Lagier RJ, Di Bisceglie AM, Shih JW, et al. Evaluation of branched DNA signal amplification for the detection of hepatitis C virus RNA. J Viral Hep 1995; 2: 121132.
  • 39
    Farci P, Alter HJ, Shimoda A, Govindarajan S, Cheung C, Melpolder JC, Sacher RA, et al. Hepatitis C virus-associated fulminant hepatic failure. N Engl J Med 1996; 335: 631634.
  • 40
    Takaki A, Wiese M, Maertens G, Depla E, Seifert U, Liebetrau A, Miller JL, et al. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med 2000; 6: 578582.
  • 41
    Gerlach JT, Zachoval R, Gruener NH, Jung M-C, Ulsenheimer A, Schraut W, Waechtler M, et al. Acute hepatitis C: natural course and response to antiviral treatment [Abstract]. Hepatology 2001; 34: 341A.
  • 42
    Villano SA, Vlahov D, Nelson KE, Cohn S, Thomas DL. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology 1999; 29: 908914.
  • 43
    Yeo AET, Ghany M, Conry-Cantilena C, Melpolder JC, Kleiner DE, Shih JWK, Hoofnagle JH, et al. Stability of HCV-RNA level and its lack of correlation with disease severity in asymptomatic chronic hepatitis C virus carriers. J Viral Hep 2001; 8: 256263.
  • 44
    Yokosuka O, Kojima H, Imazeki F, Tagawa M, Saisho H, Tamatsukuri S, Omata M. Spontaneous negativation of serum hepatitis C virus RNA is a rare event in type C chronic liver diseases: analysis of HCV RNA in 320 patients who were followed for more than 3 years. J Hepatol 1999; 31: 394399.
  • 45
    Conry-Cantilena C, Van Raden M, Gibble J, Melpolder J, Shakil AO, Viladomiou L, Cheung L, et al. Routes of interferon, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N Engl J Med 1996; 334: 16911696.
  • 46
    Hoofnagle JH. Hepatitis C: clinical spectrum of disease. Hepatology 1997; 26 (Suppl. 1): 15S20S.
  • 47
    Shakil AO, Conry-Cantilena C, Alter HJ, Hayashi P, Kleiner DE, Tedeschi V, Krawczynsik K, et al. Volunteer blood donors with antibody to hepatitis C virus: clinical, biochemical, virologic, and histologic features. Ann Intern Med 1995; 123: 330337.
  • 48
    Martinot-Peignous X, Boyer N, Cazals-Hatem D, Pham BN, Gervais A, Le Breton V, Levy S, et al. Prospective study on anti-hepatitis C virus-positive patients with persistently normal serum alanine transaminase with or without detectable serum hepatitis C virus RNA. Hepatology 2001; 34: 10001005.
  • 49
    Haber MM, West AB, Haber AD, Reuben A. Relationship of aminotransferases to liver histological status in chronic hepatitis C. Am J Gastroenterol 1995; 90: 12501257.
  • 50
    Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994; 19: 15131520.
  • 51
    Ghany MG, Kleiner DE, Alter HJ, Doo E, Khokhar F, Park Y, Liang TJ, et al. Progression of fibrosis in early stages of chronic hepatitis C [Abstract]. Hepatology 2000; 32: 496A.
  • 52
    Farci P, Shimoda A, Coiana A, Diaz G, Peddis G, Melpolder JC, Strazzera A, et al. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 2000; 288: 339344.
  • 53
    Gruner NH, Gerlach TJ, Jung MC, Diepolder HM, Schirren CA, Schraut WW, Hoffmann R, et al. Association of hepatitis C virus-specific CD8 + T cells with viral clearance in acute hepatitis C. J Infect Dis 2000; 181: 15281536.
  • 54
    Lechner F, Wong DK, Dunbar PR, Chapman R, Chung RT, Dohrenwend P, Robbins G, et al. Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 2000; 191: 14991512.
  • 55
    Cerny A, Chisari FV. Pathogenesis of chronic hepatitis C: immunological features of hepatic injury and viral persistence. Hepatology 1999; 30: 595601.
  • 56
    Christie JM, Healey CJ, Watson J, Wong VS, Duddridge M, Snowden N, Rosenberg WM, et al. Clinical outcome of hypogammaglobulinemic patients following an outbreak of acute hepatitis C: 2 year follow up. Clin Exp Immunol 1997; 110: 48.
  • 57
    Thomas DL, Astemborski J, Rai RM, Anania FA, Schaeffer M, Galai N, Nolt K, et al. The natural history of hepatitis C virus infection: host, viral and environmental factors. JAMA 2000; 284: 450456.
  • 58
    Seeff LB, Hollinger FB, Alter HJ, Wright EC, Cain CM, Buskell ZJ, Ishak KG, et al. Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: a National Heart, Lung, and Blood Institute collaborative study. Hepatology 2001; 33: 455463.
  • 59
    Bellentani S, Tiribelli C. The spectrum of liver disease in the general population: lesson from the Dionysos study. J Hepatol 2001; 35: 531537.
  • 60
    Sasaki N, Matsui A, Momoi M, Tsuda F, Okamoto H. Loss of circulating hepatitis C virus in children who developed a persistent carrier state after mother-to-baby transmission. Pediatr Res 1997; 42: 263267.
  • 61
    Vogt M, Lang T, Froesner G, Klingler CH, Sendl AF, Zeller A, Wiebecke B, et al. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood donor screening. N Engl J Med 1999; 341: 866870.
  • 62
    Strickland DK, Riely CA, Patrick CC, Jones-Wallace D, Boyett JM, Waters B, Fleckenstein JF, et al. Hepatitis C infection among survivors of childhood cancer. Blood 2000; 95: 30653070.
  • 63
    Kenny-Walsh E, for the Irish Hepatology Research Group. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. N Engl J Med 1999; 340: 12281233.
  • 64
    Wiese M, Berr F, Lafrenz M, Porst H, Oesen U, for the East German Hepatitis C Study Group. Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in Germany: a 20-year multicenter study. Hepatology 2000; 32: 9196.
  • 65
    Howell C, Jeffers L, Hoofnagle JH. Hepatitis C in African Americans. Summary of a workshop. Gastroenterology 2000; 119: 13851396.
  • 66
    Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, Nevens F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997; 112: 463472.
  • 67
    Pawlotsky JM, Ben Yahia M, Andre C, Viosin MC, Intrator L, Roudot-Thoraval F, Deforges L, et al. Immunological disorders in C virus chronic active hepatitis: a prospective case-control study. Hepatology 1994; 19: 841848.
  • 68
    Cacoub P, Renou C, Rosenthal E, Cohen P, Loury I, Loustaud-Ratti V, Yamamoto AM, et al. Extrahepatic manifestations associated with hepatitis C virus infection. A prospective multicenter study of 321 patients. The GERMIVIC Groupe d'Etude et de Recherche en Medecine Interne et Maladies Infectieuses sur le Virus de l'Hepatite C. Medicine (Baltimore) 2000; 79: 4756.
  • 69
    Agnello V, Chung RT, Kaplan LM. A role of hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med 1992; 327: 14901495.
  • 70
    Misiani R, Bellavita P, Fenili D, Borelli G, Marchesi D, Massazza M, Vendramin G, et al. Hepatitis C virus infection in patients with essential mixed cryoglobulinemia. Ann Intern Med 1992; 117: 573577.
  • 71
    Misiani R, Bellavita P, Fenili D, Vicari O, Marchesi D, Sironi PL, Zilio P, et al. Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus. N Engl J Med 1994; 330: 751756.
  • 72
    Lunel F, Cacoub P. Treatment of autoimmune and extrahepatic manifestations of hepatitis C virus infection. J Hepatol 1999; 31: 210216.
  • 73
    Zuckerman E, Zuckerman T, Levine AM, Douer D, Gutekunst K, Mizokami M, Qian DG, et al. Hepatitis C virus infection in patients with B-cell non-Hodgkin lymphoma. Ann Intern Med 1997; 127: 423428.
  • 74
    Hausfater P, Cacoub P, Sterkers Y, Thibault V, Amoura Z, Nguyen L, Ghillani P, et al. Hepatitis C virus infection and lymphoproliferative diseases: prospective study on 1,576 patients in France. Am J Hematol 2001; 67: 168171.
  • 75
    Silvestri F, Pipan C, Barillari G, Zaja F, Fanin R, Infanti L, Russo D, et al. Prevalence of hepatitis C virus infection in patients with lymphoproliferative disorders. Blood 1996; 87: 42964301.
  • 76
    Johnson RJ, Gretch DR, Yamabe H, Hart J, Bacchi CE, Hartwell P, Couser WG, et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med 1993; 328: 465470.
  • 77
    Haddad J, Deny P, Munz-Gotheil C, Ambrosini JC, Trinchet JC, Pateron D, Mal F, et al. Lymphocytic sialadenitis of Sjogren's syndrome associated with chronic hepatitis C virus liver disease. Lancet 1992; 339: 321323.
  • 78
    Tanei R, Watanabe K, Nishiyama S. Clinical and histopathologic analysis of the relationship between lichen planus and chronic hepatitis C. J Dermatol 1995; 22: 316323.
  • 79
    Heckmann JG, Kayser C, Heuss D, Manger B, Blum HE, Neundorfer B. Neurological manifestations of chronic hepatitis C. J Neurol 1999; 246: 486491.
  • 80
    Bonkovsky HL, Poh-Fitzpatrick M, Pimstone N, Obando J, Di Bisceglie A, Tattrie C, Tortorelli K, et al. Porphyria cutanea tarda, hepatitis C, and HFE gene mutations in North America. Hepatology 1998; 27: 16611669.